Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 8/20 | 0.76 |
| ▸ | HTR1D | P28221 | 5/20 | 0.76 |
| ▸ | HTR1A | P08908 | 3/20 | 0.71 |
| ▸ | HTR6 | P50406 | 8/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | GABRP | O00591 | 1/20 | 0.58 |
| ▸ | GABRD | O14764 | 1/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.58 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122175 | 1.00 | HTR1B (0.76) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL1122542 | 1.00 | HTR1B (0.76) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL3381424 | 0.88 | SLC6A4 (0.71) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL3381418 | 0.88 | SLC6A4 (0.71) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL8208343 | 0.86 | HTR1B (1.00) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL8208346 | 0.86 | HTR1B (1.00) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL8508432 | 0.86 | HTR1B (1.00) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL8790004 | 0.85 | HTR1B (0.80) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL8790009 | 0.85 | HTR1B (0.80) | HTR1BHTR1DHTR1AHTR6CHRM2 | |
| SCHEMBL7853144 | 0.85 | GABRP (0.60) | HTR1BHTR1DHTR1AHTR6GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101247853-B | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-12 | — | — | CN | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | disclosed |
| US-5498626-A | Acylaminoindole derivatives as 5-ht1 agonists | PFIZER INC. (US) | 1996-03-12 | — | — | US | disclosed |
| EP-0635015-A1 | ACYLAMINOINDOLE DERIVATIVES AS 5-HT1 AGONISTS. | PFIZER (US) | 1995-01-25 | — | — | EP | disclosed |
| CN-1094727-A | The 5-(hetero) aryl indole derivatives | PFIZER (US) | 1994-11-09 | — | — | CN | disclosed |
| EP-0619805-A1 | INDOLE DERIVATIVES | PFIZER HOSPITAL PRODUCTS, INC. (US) | 1994-10-19 | — | — | EP | disclosed |
| EP-0592438-A1 | INDOLE DERIVATIVES. | PFIZER (US) | 1994-04-20 | — | — | EP | disclosed |
| WO-1993021180-A1 | ACYLAMINOINDOLE DERIVATIVES AS 5-HT1 AGONISTS | PFIZER INC. (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993011106-A1 | INDOLE DERIVATIVES | PFIZER, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
| CN-1072679-A | INDOLE DERIVATIVES | PFIZER (US) | 1993-06-02 | — | — | CN | disclosed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | HTR1B 221/4885HTR1D 511/4885HTR1A 91/4885 |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | HTR1B 221/4885HTR1D 511/4885HTR1A 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.